Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.9894
- Book/Share 38.2151
- PB 7.7563
- Debt/Equity 0.5957
- CurrentRatio 0.7761
- ROIC 0.3599
- MktCap 1317552882347.1384
- FreeCF/Share 14.1116
- PFCF 21.0012
- PE 12.6986
- Debt/Assets 0.1976
- DivYield 0.0366
- ROE 0.6695
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | NVO | Jefferies | -- | Underperform | -- | -- | Oct. 27, 2025 |
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
News
Virtus SGA International Growth Q3 2025 Portfolio Activity
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Neutral
At the beginning of the quarter, Virtus liquidated its position in Novo Nordisk (NVO) and used the proceeds to fund a new position in Japanese retail holding company, Fast Retailing (FRCOY). We also initiated a position in the Chinese technology company, Alibaba (BABA), by trimming a number of existing holdings. Additional shares were purchased in Adyen (ADYEY), Atlassian (TEAM), and SAP (SAP) on weakness, while positions in Arm Holdings (ARM) and L'Oreal (LRLCF) among others were trimmed on strength.
Read More
GLP-1 prices are dropping: Who exactly will benefit?
Published: November 11, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Bertha Coombs asks President Trump and his team at the White House's announcement on lower prices for Eli Lilly and Novo Nordisk's GLP-1 medications, if those new prices will extend to commercial plans. Half of Americans are covered by employer and private health plans, many of which don't cover GLP-1s for weight loss because of the cost.
Read More
3 Buy-And-Forget Dividend Stocks With Snowballing Payouts
Published: November 11, 2025 by: 24/7 Wall Street
Sentiment: Positive
If the headline yield today is not something you're concerned with, and you pay more attention to how fast a yield can grow, then it's worth buying dividend stocks you can forget about for decades.
Read More
Pfizer to acquire Metsera after winning bidding contest against Novo Nordisk
Published: November 10, 2025 by: Proactive Investors
Sentiment: Positive
Metsera (NASDAQ:MTSR) announced that it has entered into an amended merger agreement with Pfizer Inc (NYSE:PFE, ETR:PFE), under which Pfizer will acquire the biotech company for up to $86.25 per share, valuing it at about $10 billion. The offer consists of $65.60 per share in cash and a contingent value right (CVR) for additional payments of up to $20.65 per share based on clinical and regulatory milestones.
Read More
Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Negative
NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.
Read More
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
Published: November 07, 2025 by: CNBC
Sentiment: Positive
President Donald Trump struck landmark deals with Eli Lilly and Novo Nordisk that could mark a turning point in access to their costly blockbuster obesity drugs. Medicare will start covering GLP-1s for obesity for certain patients for the first time beginning in mid-2026 – a shift that some experts say will open access to millions of older adults and could spur more employers and other private insurers to follow suit.
Read More
Eli Lilly, Novo Nordisk's Historic GLP-1 Pricing Deals - What Investors Need To Know
Published: November 07, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S and Eli Lilly and Company have agreed to slash US prices for Ozempic, Wegovy, Mounjaro, and Zepbound, expanding Medicare/Medicaid access. NVO's stock has dropped sharply in 2025, but the new deal could boost long-term revenue by increasing drug accessibility and wiping out compounded competition. Despite price cuts, LLY's strong US manufacturing presence and blockbuster tirzepatide sales position it for continued growth and potential $1T market cap.
Read More
Trump administration reaches deal to lower prices of obesity and diabetes drugs
Published: November 06, 2025 by: Proactive Investors
Sentiment: Positive
The Trump administration has announced agreements with pharmaceutical companies Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) to reduce the cost of GLP-1 medications used to treat obesity, diabetes, and related conditions. The initiative seeks to expand access and affordability for millions of Americans, including those covered by Medicare and Medicaid.
Read More
Eli Lilly and Novo Nordisk lower GLP-1 drug costs in new deal with Trump.
Published: November 06, 2025 by: Yahoo Finance
Sentiment: Positive
About Yahoo Finance: Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life. - Get the latest news and data at finance.yahoo.com - Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO) - Follow Yahoo Finance on social: X: http://twitter.com/YahooFinance Instagram: https://www.instagram.com/yahoofinance/?hl=en TikTok: https://www.tiktok.com/@yahoofinance?lang=en Facebook: https://www.facebook.com/yahoofinance/ LinkedIn: https://www.linkedin.com/company/yahoo-finance
Read More
Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk
Published: November 06, 2025 by: CNBC
Sentiment: Positive
President Donald Trump struck landmark deals with Eli Lilly and Novo Nordisk to slash the prices of their blockbuster weight loss drugs. Under the agreements, the monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350, depending on the dosage and insurance coverage a patient has.
Read More
Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
Published: November 06, 2025 by: PRNewsWire
Sentiment: Neutral
A post hoc analysis of REDEFINE 1 demonstrated a 10.9 mmHg reduction in systolic blood pressure with investigational CagriSema (2.4 mg/2.4 mg), allowing 40% of people on blood pressure medications to reduce or stop their medication1 CagriSema treatment demonstrated a nearly 70% reduction in a key inflammatory marker associated with increased cardiovascular risk2 Data showed that fewer people on CagriSema were at intermediate-to-high risk of developing atherosclerotic cardiovascular disease (ASCVD) within the next 10 years3 PLAINSBORO, N.J. and BAGSVÆRD, Denmark , Nov. 6, 2025 /PRNewswire/ -- At ObesityWeek ® (November 4-7 in Atlanta, GA), Novo Nordisk presented new post hoc …
Read More
Novo CEO says its bid for Metsera is higher
Published: November 06, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk CEO Mike Doustdar said during a White House event on Thursday that the company's bid for obesity biotech Metsera is higher than the one from rival Pfizer Inc. , which has sued both Metsera and Novo over the terms of their rival deal.
Read More
Novo Nordisk expects global sales to decline by low single digits in 2026
Published: November 06, 2025 by: Reuters
Sentiment: Negative
Novo Nordisk expects global sales to decline by low-single-digit percentage in 2026 after the drugmaker unveiled a deal on Thursday to slash prices of popular GLP-1 weight‑loss drugs for U.S. government-backed insurance programs and cash payers.
Read More
Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know.
Published: November 06, 2025 by: The Motley Fool
Sentiment: Negative
Sluggish growth for Novo Nordisk's GLP-1 drugs caused the company to again reduce its full-year sales guidance. Novo Nordisk faces challenges from the continued compounding of GLP-1 drugs and increased competition.
Read More
Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost
Published: November 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Novo Nordisk has agreed with the U.S.
Read More
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
Published: November 06, 2025 by: CNBC
Sentiment: Positive
President Donald Trump announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatments. The agreements will lower prices of GLP-1 drugs on Medicare and Medicaid and offer the treatments directly to consumers at a discount on a website the Trump administration is launching in January 2026 called TrumpRx.gov.
Read More
Trump White House confirms pricing deal with weight-loss-drug giants Eli Lilly, Novo Nordisk
Published: November 06, 2025 by: Market Watch
Sentiment: Positive
President Donald Trump's administration confirmed Thursday that it has reached a deal with Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to certain Medicare and Medicaid beneficiaries and to users of TrumpRx.gov, the administration's new direct-to-consumer website.
Read More
What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?
Published: November 06, 2025 by: Reuters
Sentiment: Positive
Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment their pipeline in the booming weight-loss drug market.
Read More
Novo Nordisk: Problems Compound, But Stock Still Cheap (Rating Downgrade)
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk A/S is downgraded to Buy due to emerging risks in the weight loss sector and recent Q3 2025 earnings results. NVO stock's valuation remains historically low, showing signs that a lot of risks may be priced in. A potential partnership with Hims could boost NVO's revenue growth through new channels but may further impact margins.
Read More
Why Novo Nordisk's Q3 Miss Is A Buying Opportunity
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S delivered mixed Q3 '25 results, with modest revenue growth but a 27% drop in net profit due to higher financing costs. NVO's GLP-1 franchise, led by Ozempic and Wegovy, faces moderated growth and supply constraints, yet remains a key revenue driver at 49% of sales. Promising Phase 3 data for oral Wegovy supports its potential as the first oral GLP-1 obesity therapy, with an FDA decision expected by end-2025.
Read More
Novo Nordisk Q3: Why I'm Not Giving Up Yet
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S shares have plunged nearly 70%, yet the company remains a leader in GLP-1 and obesity drugs with strong growth catalysts. Despite fierce competition and a recent reset phase, NVO's Q3 2025 showed net sales up 15% at CER and operating profit up 21% excluding one-offs. Obesity Care, led by Wegovy, saw 41% sales growth at CER, and the upcoming Wegovy pill approval could significantly boost adoption and revenue.
Read More
Novo Nordisk Is Seeing Slowing Demand for GLP-1s Wegovy and Ozempic
Published: November 05, 2025 by: Investopedia
Sentiment: Negative
U.S.-listed shares of Novo Nordisk (NVO) fell after the drugmaker scaled back its outlook, citing disappointing demand for its GLP-1 weight loss and diabetes drugs as competition in the sector increases.
Read More
Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Negative
NVO's Q3 profit and revenues miss expectations as Wegovy and Ozempic growth slows amid U.S. compounding and pricing headwinds.
Read More
Novo Nordisk slashes full-year sales forecast amid competition in diabetes and obesity markets
Published: November 05, 2025 by: Proactive Investors
Sentiment: Negative
Novo Nordisk (NYSE:NVO) shares moved lower after the drugmaker posted weaker-than-expected revenue growth for Q3 and adjusted its full-year guidance, citing reduced growth expectations for its diabetes and obesity products amid increased competition and pricing pressure. Novo Nordisk downwardly revised its guidance, now expecting full-year 2025 sales growth of 8% to 11% at constant exchange rates (CER), down from its earlier guidance of 8% to 14%.
Read More
Healthy Returns: What to know about Pfizer and Novo Nordisk's bidding war over obesity biotech Metsera
Published: November 05, 2025 by: CNBC
Sentiment: Positive
Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to extending tax credits.
Read More
Novo Nordisk CEO Mike Doustdar on $10B Metsera bid, expanding use of obesity drugs
Published: November 05, 2025 by: CNBC Television
Sentiment: Positive
Novo Nordisk CEO Mike Doustdar joins 'Squawk Box' to discuss the company's quarterly earnings results, the company's bid for obesity biotech company Metsera, negotiations with the Trump administration to sell some of its obesity drugs to consumers at a lower rate, expanding the use of obesity drug, and more.
Read More
Novo Nordisk tops Pfizer in bidding war for obesity startup Metsera
Published: November 04, 2025 by: Proactive Investors
Sentiment: Positive
Novo Nordisk (NYSE:NVO) has outbid Pfizer Inc (NYSE:PFE, ETR:PFE) in a heated contest for obesity-focused biotech Metsera (NASDAQ:MTSR), with the Danish drugmaker's revised offer valuing the company at roughly $10 billion, compared with Pfizer's $8.1 billion proposal. Metsera's board on Tuesday declared Novo Nordisk's amended bid “superior,” setting the stage for a potential acquisition that could reshape the obesity treatment landscape.
Read More
Pfizer and Novo Nordisk both raise bids for Metsera
Published: November 04, 2025 by: CNBC Television
Sentiment: Positive
CNBC's David Faber breaks down the latest details about a bidding war between Pfizer and Novo Nordisk for Metsera.
Read More
Lilly and Novo Nordisk near White House deal on obesity drug prices, Endpoints New reports
Published: November 04, 2025 by: Reuters
Sentiment: Positive
Eli Lilly and Novo Nordisk are preparing to announce new drug pricing deals with the White House, including for their blockbuster weight loss drugs, in return for coverage of products under Medicare, Endpoints New reported on Tuesday, citing sources familiar with the matter.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Lars Fruergaard Jorgensen
- Employees 77406